Definium Therapeutics reported positive top-line results from a first randomized, double-blind, placebo-controlled Phase 3 study of single-dose DT-120 (lysergide) in major depressive disorder. The company said the oral-disintegrating 100 µg tablet produced a larger MADRS score reduction than placebo. Six weeks after dosing, patients on DT-120 saw a 13.3-point drop versus 5.2 on placebo, with benefit largely maintained at 12 weeks (11.0-point drop vs 3.6 on placebo). The dataset strengthens the argument for continued development toward possible regulatory review. Management characterized the results as a meaningful advancement for psychedelic-assisted psychiatry, with the company positioned to discuss next steps with regulators as the program matures.